While HIF2α has been found to have a clear oncogenic role in ccRCC with a HIF2α inhibitor in the drug development pipeline23–25, evidence for the role of HIF1α in this disease has been conflicting. Here, HIF1A is linked to nonpapillary renal cell carcinoma.